Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
55
HLN Quote, Financials, Valuation and Earnings
Last price:
$9.91
Seasonality move
:
3.2%
Day range:
$9.85 - $9.95
52-week range:
$8.71 - $11.42
Dividend yield:
1.77%
P/E ratio:
23.30x
P/S ratio:
3.16x
P/B ratio:
1.97x
Volume:
10.9M
Avg. volume:
9.7M
1-year change:
4.43%
Market cap:
$44.5B
Revenue:
$14.4B
EPS (TTM):
$0.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HLN
Haleon Plc
|
$3.8B | $0.32 | 1.58% | 8.98% | $11.82 |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
$24.3M | -$0.40 | 84624.25% | -288.08% | $9.63 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | $8.01 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HLN
Haleon Plc
|
$9.91 | $11.82 | $44.5B | 23.30x | $0.06 | 1.77% | 3.16x |
|
APM
Aptorum Group Ltd.
|
$1.05 | -- | $7.5M | 8.94x | $0.00 | 0% | 6.32x |
|
AUTL
Autolus Therapeutics Plc
|
$1.81 | $9.63 | $481.7M | -- | $0.00 | 0% | 9.40x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.35 | $17.94 | $2M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$3.37 | $104.00 | $14M | -- | $0.00 | 0% | -- |
|
TLSA
Tiziana Life Sciences Ltd.
|
$1.48 | $8.01 | $177.9M | -- | $0.00 | 0% | 2,803.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HLN
Haleon Plc
|
38.17% | -0.309 | -- | 0.75x |
|
APM
Aptorum Group Ltd.
|
-- | 0.929 | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.916 | 74.96% | 4.83x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -0.262 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HLN
Haleon Plc
|
$2B | $448.1M | 5.64% | 8.91% | 14.46% | $921M |
|
APM
Aptorum Group Ltd.
|
-- | -- | -- | -- | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
TLSA
Tiziana Life Sciences Ltd.
|
-- | -- | -- | -- | -- | -- |
Haleon Plc vs. Competitors
-
Which has Higher Returns HLN or APM?
Aptorum Group Ltd. has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat Aptorum Group Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon Plc55.38% $0.06 $32.9B APMAptorum Group Ltd.-- -- -- -
What do Analysts Say About HLN or APM?
Haleon Plc has a consensus price target of $11.82, signalling upside risk potential of 19.3%. On the other hand Aptorum Group Ltd. has an analysts' consensus of -- which suggests that it could grow by 14185.71%. Given that Aptorum Group Ltd. has higher upside potential than Haleon Plc, analysts believe Aptorum Group Ltd. is more attractive than Haleon Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon Plc1 1 0 APMAptorum Group Ltd.0 0 0 -
Is HLN or APM More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aptorum Group Ltd. has a beta of -0.148, suggesting its less volatile than the S&P 500 by 114.791%.
-
Which is a Better Dividend Stock HLN or APM?
Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.77%. Aptorum Group Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. Aptorum Group Ltd. pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or APM?
Haleon Plc quarterly revenues are $3.5B, which are larger than Aptorum Group Ltd. quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than Aptorum Group Ltd.'s net income of --. Notably, Haleon Plc's price-to-earnings ratio is 23.30x while Aptorum Group Ltd.'s PE ratio is 8.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.16x versus 6.32x for Aptorum Group Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon Plc3.16x 23.30x $3.5B $295.8M APMAptorum Group Ltd.6.32x 8.94x -- --
-
Which has Higher Returns HLN or AUTL?
Autolus Therapeutics Plc has a net margin of 8.37% compared to Haleon Plc's net margin of -373.3%. Haleon Plc's return on equity of 8.91% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon Plc55.38% $0.06 $32.9B AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About HLN or AUTL?
Haleon Plc has a consensus price target of $11.82, signalling upside risk potential of 19.3%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.63 which suggests that it could grow by 432.23%. Given that Autolus Therapeutics Plc has higher upside potential than Haleon Plc, analysts believe Autolus Therapeutics Plc is more attractive than Haleon Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon Plc1 1 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is HLN or AUTL More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.012, suggesting its more volatile than the S&P 500 by 101.185%.
-
Which is a Better Dividend Stock HLN or AUTL?
Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.77%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or AUTL?
Haleon Plc quarterly revenues are $3.5B, which are larger than Autolus Therapeutics Plc quarterly revenues of $21.1M. Haleon Plc's net income of $295.8M is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Haleon Plc's price-to-earnings ratio is 23.30x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.16x versus 9.40x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon Plc3.16x 23.30x $3.5B $295.8M AUTLAutolus Therapeutics Plc9.40x -- $21.1M -$78.6M
-
Which has Higher Returns HLN or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon Plc55.38% $0.06 $32.9B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About HLN or BDRX?
Haleon Plc has a consensus price target of $11.82, signalling upside risk potential of 19.3%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 7468.14%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Haleon Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Haleon Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon Plc1 1 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is HLN or BDRX More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock HLN or BDRX?
Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.77%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or BDRX?
Haleon Plc quarterly revenues are $3.5B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Haleon Plc's price-to-earnings ratio is 23.30x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.16x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon Plc3.16x 23.30x $3.5B $295.8M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns HLN or NCNA?
NuCana Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon Plc55.38% $0.06 $32.9B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About HLN or NCNA?
Haleon Plc has a consensus price target of $11.82, signalling upside risk potential of 19.3%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 617110.68%. Given that NuCana Plc has higher upside potential than Haleon Plc, analysts believe NuCana Plc is more attractive than Haleon Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon Plc1 1 0 NCNANuCana Plc0 1 0 -
Is HLN or NCNA More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.248%.
-
Which is a Better Dividend Stock HLN or NCNA?
Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.77%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or NCNA?
Haleon Plc quarterly revenues are $3.5B, which are larger than NuCana Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than NuCana Plc's net income of -$378.9K. Notably, Haleon Plc's price-to-earnings ratio is 23.30x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.16x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon Plc3.16x 23.30x $3.5B $295.8M NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns HLN or TLSA?
Tiziana Life Sciences Ltd. has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat Tiziana Life Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HLNHaleon Plc55.38% $0.06 $32.9B TLSATiziana Life Sciences Ltd.-- -- -- -
What do Analysts Say About HLN or TLSA?
Haleon Plc has a consensus price target of $11.82, signalling upside risk potential of 19.3%. On the other hand Tiziana Life Sciences Ltd. has an analysts' consensus of $8.01 which suggests that it could grow by 441.23%. Given that Tiziana Life Sciences Ltd. has higher upside potential than Haleon Plc, analysts believe Tiziana Life Sciences Ltd. is more attractive than Haleon Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNHaleon Plc1 1 0 TLSATiziana Life Sciences Ltd.1 0 0 -
Is HLN or TLSA More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tiziana Life Sciences Ltd. has a beta of 0.024, suggesting its less volatile than the S&P 500 by 97.65%.
-
Which is a Better Dividend Stock HLN or TLSA?
Haleon Plc has a quarterly dividend of $0.06 per share corresponding to a yield of 1.77%. Tiziana Life Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 41.96% of its earnings as a dividend. Tiziana Life Sciences Ltd. pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLN or TLSA?
Haleon Plc quarterly revenues are $3.5B, which are larger than Tiziana Life Sciences Ltd. quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than Tiziana Life Sciences Ltd.'s net income of --. Notably, Haleon Plc's price-to-earnings ratio is 23.30x while Tiziana Life Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.16x versus 2,803.69x for Tiziana Life Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNHaleon Plc3.16x 23.30x $3.5B $295.8M TLSATiziana Life Sciences Ltd.2,803.69x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
